The Rise of Cychlorphine, Kratom, and 7-OH: Why Prevention Is the First Line of Defense

What Emerging Drugs Are Driving This Threat?

What is cychlorphine?

Cychlorphine (N-propionitrile chlorphine) is a synthetic opioid in the “orphine” class, roughly 10 times more potent than fentanyl based on lab pharmacology data, according to the CFSRE. Like other opioids, it activates the brain’s receptors for pain relief, euphoria, and sedation, and it can suppress the brain’s ability to regulate breathing. It has no approved medical use.

Cychlorphine is being pressed into counterfeit pills and mixed into fentanyl, methamphetamine, and cocaine, often without users knowing. The CFSRE first detected it in mid-2024 and has tracked a rise in fatal overdoses involving it since mid-2025. By early 2026, it had been identified in 25 fatal overdose cases tested by the CFSRE and tentatively identified in more than 100 toxicology cases at NMS Labs, across nine U.S. states and three Canadian provinces.

How dangerous is cychlorphine?

One pill can be fatal. In April 2026, a 16-year-old in San Francisco died in his bedroom after taking a pill. His mother gave him two doses of Narcan, but he could not be revived. His autopsy showed no fentanyl. It showed cychlorphine, the first time the drug had appeared on a San Francisco coroner’s report, as The New York Times reported. Police later arrested four suspected dealers and seized more than 20,000 suspected counterfeit pills, according to ABC7 San Francisco.

Can standard tests detect cychlorphine?

No. San Francisco officials said available test kits do not detect it, according to ABC7 San Francisco, and a DEA special agent in charge described it as nearly impossible to test for on the street, as reported by ABC7 Chicago. Confirmation typically requires forensic lab testing.

What should communities know about naloxone and cychlorphine?

Cychlorphine responds to naloxone (Narcan) like other opioids, but people can die once they have stopped breathing for some time, according to Dr. Hilary Kunins of the San Francisco Department of Public Health, speaking to CBS Bay Area. That makes naloxone access and overdose-response education essential parts of any community prevention strategy.

What is kratom?

Kratom comes from the leaves of a tropical evergreen tree native to Southeast Asia. Its compounds interact with the brain’s opioid receptors, according to the CDC. It is sold as powders, capsules, liquids, and gummies at gas stations, smoke shops, and online, which leads many consumers to assume it is natural and safe. It is not FDA approved.

Regular use can lead to dependence. People who meet criteria for kratom use disorder typically show tolerance, withdrawal, using more than intended, and cravings, according to a review by researchers at Johns Hopkins and the National Institute on Drug Abuse.

Harms are rising fast. U.S. poison centers received 14,449 kratom exposure reports from 2015 to 2025, with a record 3,434 in 2025 alone, per the CDC’s MMWR. Kratom-only hospitalizations grew from 43 to 538 over the same period, and 233 deaths were linked to kratom, according to UVA Health.

What is 7-OH (7-hydroxymitragynine)?

7-OH is a concentrated compound derived from kratom, marketed alongside traditional kratom but far more potent. The FDA classifies it as an opioid that binds to opioid receptors and can be more potent than morphine. There are no FDA-approved 7-OH drugs, and it is not lawful in dietary supplements. Yet it remains easy to buy in gas stations, corner stores, and vape shops.

The timing tells the story. Kratom-related poison center reports more than doubled between 2024 and 2025, coinciding with the emergence of 7-OH products, according to Psychiatric News.

Why Can’t Regulation Keep Up With New Drugs?

New drugs move faster than the systems built to catch them. Four gaps drive the problem.

Detection gaps

Standard field tests and hospital toxicology screens are built for known drugs. Novel compounds like cychlorphine often require specialized lab testing, giving them time to spread before anyone knows they are there.

Regulatory lag

Scheduling a new drug takes time. In July 2025, the FDA recommended scheduling concentrated 7-OH products as a controlled substance. The DEA holds final authority, and the process requires rulemaking and public comment before anything is finalized. Meanwhile, products stay on shelves.

Legal retail availability

Kratom and 7-OH products are sold over the counter next to energy drinks and nicotine. Easy access signals safety, leading people to underestimate potency and addiction risk.

Crackdowns shift the supply

When one drug is controlled, another fills the gap. After China placed nitazene analogues under generic control in July 2025, nitazene positivity declined while orphine positivity climbed, led largely by cychlorphine, according to the CFSRE. Enforcement alone becomes a game of whack-a-mole.

Why Is Prevention the Most Effective Response?

Prevention works before exposure, on any substance. It doesn’t need to know which drug is trending next. Regulation reacts to one substance at a time. Prevention builds the knowledge, skills, and early warning systems that protect people from all of them. Awareness campaigns move faster than rulemaking. Screening catches risky use before it becomes addiction. And early intervention stops the progression before a person ever encounters a potent synthetic opioid.

What Does Effective Prevention Look Like?

Effective prevention reaches people before they ever use, when early warning signs appear, and when they need help now. Digital prevention tools let communities do all three at scale, and update the message as fast as the drug supply changes.

Education and awareness that keeps pace

Generic “drugs are bad” campaigns miss the moment. People need to know the names, forms, and local risks of what is circulating now, including products sold legally on gas station shelves.

• Interactive quizzes turn awareness into engagement. Instead of a poster people walk past, a short, gamified quiz tests what someone knows about fake pills, cannabis, vaping, binge drinking, or opioids and fentanyl. Each answer triggers immediate feedback: accurate facts, what peers actually do, and where to find local help. Because quizzes test knowledge rather than collect personal health information, they can often reach youth without the consent requirements of clinical screening.
• Content moves as fast as the threat. With ePrevention, quiz questions, educational messages, and local resources are customizable, so a community can add a new substance like cychlorphine or 7-OH as soon as it shows up locally. No waiting on a new print campaign.
• Reach is built in. ePrevention includes a ready-made marketing toolkit: customizable email and newsletter templates, posters, flyers, social media content, and web copy. Every quiz and screener gets its own link and QR code, white-labeled with the organization’s brand, so it can live anywhere people are: school hallways, pharmacy counters, bars, community events, and health plan portals.

Screening and early intervention

Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based model designed to serve youth and adults at risk for harmful substance use, whether or not they have a diagnosed disorder, according to the Title IV-E Prevention Services Clearinghouse. Screening typically takes 5 to 10 minutes.

Not everyone will raise their hand to a doctor, teacher, or parent. ePrevention automates SBIRT so people can check their own risk privately, anytime, on their phone. Screenings can be anonymous or identifiable, and anonymous screening tends to elicit more honest answers.

• Validated screeners, matched to the audience. Communities choose from a library of clinically validated tools, including the AUDIT and DAST-10 for adults, the CRAFFT 2.1, S2BI, and BSTAD for adolescents, and the PHQ-9 and GAD-7 for co-occurring depression and anxiety.
• Smart interventions, not generic results. A rules engine reads each person’s answers and delivers a brief intervention matched to their risk: educational videos (available in English and Spanish), ways to reduce risk, local treatment and support organizations, national resources like 988, or a direct referral that alerts a provider to reach out. When screening is identifiable, staff can get real-time email alerts triggered by specific answers or scores.
• Built for the field, too. Peers, quick response teams, and clinicians can run the same screeners interview-style, using the guided workflow to steer a conversation toward the right next step.

Referral to treatment

Identifying risk only matters if people get help. When someone needs more than a brief intervention, ePrevention presents referral options in the moment, from self-referral to local provider listings. Paired with eIntervention, referrals become closed loop, so organizations can confirm the connection actually happened.

Data that shows what is working

Every quiz and screening feeds a dashboard showing how people answered, where risk is concentrated, which interventions they engaged with, and which referrals were made. That gives prevention teams the evidence funders ask for and an early signal of emerging trends in their community.

The results are measurable. One provider used ePrevention to identify at-risk youth and deliver more than 690 interventions. A rural provider in Chaves County supported 813 individuals. As Precia Stuby, Executive Director of the Hancock County ADAMHS Board in Ohio, put it: “We followed the science. With CHESS Health’s automated SBIRT, (it) can be efficiently delivered across a broad community.”

How Can Communities Fund Prevention?

Prevention funding is more available than many organizations realize:

• Substance Use Prevention, Treatment, and Recovery Services Block Grant (SUBG): States must spend at least 20% of their allotment on primary prevention, according to SAMHSA.
• Opioid settlement funds: Billions flowing to states and localities over the coming years, with prevention an approved use in most jurisdictions. See our guide to allocating opioid settlement funds.
• State Opioid Response (SOR) and Drug-Free Communities (DFC) grants: Both support community prevention and early intervention.

How Communities Can Stay Ahead of What’s Next

No one can predict the next cychlorphine. New drugs will keep arriving faster than detection and regulation can respond. Prevention is the one strategy that doesn’t have to wait.

Communities that invest across the full continuum, from awareness to screening to connection to care, build a first line of defense that works on today’s threats and tomorrow’s. Consistent messaging, easy-to-access screening, and fast links to support reduce stigma, open conversations, and steer people away from harm before it starts.

Frequently Asked Questions About Emerging Drugs and Prevention

How should public health agencies respond to emerging drugs like cychlorphine? Invest in prevention that works across every substance: targeted education and awareness, community-wide screening, and fast referral pathways. Waiting on detection and scheduling for each new drug leaves communities exposed.

Why is kratom a growing public health concern? Kratom and concentrated 7-OH products are sold legally at gas stations, vape shops, and online, act on opioid receptors, and can lead to dependence. Poison center reports rose about 1,200% from 2015 to 2025, according to the CDC.

What should communities know about naloxone and cychlorphine? San Francisco health officials say cychlorphine responds to naloxone, but delays can be fatal. Naloxone access and overdose-response education belong in every community prevention strategy.

How can prevention programs keep pace with new substances? Use digital education and screening tools with customizable content and local resources, so messaging can be updated as soon as a new drug appears in the community.